NAS10026,946−5.25%S&P7,428−3.39%GOLD$4,132+1.46%BTC$75,633−5.94%VIX23.84+43.53%latest tape · as of 18:03 UTC
The Screen · Industrials · Aerospace & Defense
Lockheed Martin
LMT · a US exchange · USD · Market cap $148.7B · 123,000 employees
Lockheed Martin Corporation, an aerospace and defense company, engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services in the United States, E…
FAIL · Does not pass the screen
595.04 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price595.04 USD at the 4 Nov 2026 close
Our value readFair vs our fair value, as of 4 Nov 2026
Positioning political selling, disclosed 2026-09-23
Options put/call open interest 0.58, read 2026-11-02
Ethical does not pass the values gate
Price595.04 USD
Fair value657.76
Ethical score10.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-22Read Markup532.64+11.7% to today ✓Markdown gives way to Markup first Markup read since August
2026-10-02Read Markdown519.56+14.5% to today Markup gives way to Markdown after a 9% slide in 6 weeks
2026-08-22Read Markup571.48+4.1% to today ✓Accumulation gives way to Markup after a 9% rise in 7 weeks
2026-07-02Read Accumulation523.76+13.6% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Lockheed Martin holds its Markup at $595.04. The statistical read favours the buyers, held for 6 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 6 days
Price at the screen
$595.04
Valuation
22.85 trailing · 19.34 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.10
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Aerospace & Defense
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Lockheed Martin does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when LMT's ethical verdict changes
Today LMT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Cited by BDS movement and AFSC for supplying F-35 fighter jets and other military platforms to the Israeli Air Force. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades at roughly a 3% discount to our $657.76 fair value, narrow competitive moat, 11.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 9.5% discount to the base estimate.
Third-party analyst targets: 21 covering, consensus Buy. The average target sits +9% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LMT trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup$595.04-1.5%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627.
2026-10-29Markup$604.18+13.4%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627.
2026-10-22Markup · changed$532.64+0.0%Entry 19
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$532.64+0.0%Entry 18
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$532.64+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markdown$532.64+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$532.64+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markdown$532.64+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$532.64+4.5%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$509.59+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (19 analysts) rates it hold, with a mean price target of $627. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
